Not Again! More Diabetes Drug Dangers...
October 02, 2007
Two more studies published in the prominent medical journal JAMA have raised questions about the safety of both Avandia and Actos, two popular diabetes medications.
Earlier this year, a combined analysis of more than 40 studies, published in the New England Journal of Medicine, found that Avandia, made by GlaxoSmithKline, doubled the risks of heart failure and raised the risks of heart attack by 42 percent.
This finding was corroborated by yet another combined analysis by researchers from Wake Forest University. This time they limited the analysis to four long-term studies. Their findings were almost identical, and Dr. Sonal Singh, co-author of the study, said the FDA should consider withdrawing Avandia from the market.
“If you use Avandia to treat patients with type 2 diabetes,” said Singh, “their chance of getting heart failure due to Avandia is one in 30, and their risk of having a heart attack is one in 220. All due to the drug.”
Additionally, a second study by researchers at the Cleveland Clinic, found that Actos, a similar drug made by Takeda, actually lowered the risks of heart attacks, strokes, and death by about 20 percent but, like Avandia, also raised the risks of heart failure.
Journal of the American Medical Association September 12, 2007;298(10):1189-95
New England Journal of Medicine June 14, 2007; 356:2457-2471 (Free Full-Text Study)
New York Times September 12, 2007